Insider · CIK 0001951238
Justin Chakma
officer
Files at SPRY (ARS Pharmaceuticals, Inc.). First filing Nov 27, 2024, latest Dec 13, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $7.1M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRY: ARS Pharmaceuticals, Inc.
SPRYOct 9, 2026 · close 4.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | ARS Pharmaceuticals, Inc. | $1.8M 144,605 shares | -57% | - | |
| 45Moderate | ARS Pharmaceuticals, Inc. | $658k 50,000 shares | -27% | - | |
| 60Notable | ARS Pharmaceuticals, Inc. | $2.0M 144,640 shares | -80% | - | |
| 50Moderate | ARS Pharmaceuticals, Inc. | $1.2M 90,000 shares | -50% | - | |
| 65Notable | ARS Pharmaceuticals, Inc. | $1.4M 100,000 shares | -42% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | AGrant or award Stock option (right to buy)derivative | +274,100 | $0.00 | $0 | 274,100 | Jan 3, 2025 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +117,333 | $0.84 | $99k | 253,713 | Dec 13, 2024 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -117,333 | $12.27 | $1.4M | 136,380 | Dec 13, 2024 |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +27,272 | $1.44 | $39k | 163,652 | Dec 13, 2024 |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -27,272 | $12.06 | $329k | 136,380 | Dec 13, 2024 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -117,333 | $0.00 | $0 | 119,047 | Dec 13, 2024 |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -27,272 | $0.00 | $0 | 55,461 | Dec 13, 2024 |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +50,000 | $0.84 | $42k | 186,380 | Dec 12, 2024 |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -50,000 | $13.15 | $658k | 136,380 | Dec 12, 2024 |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Dec 12, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +45,000 | $0.84 | $38k | 181,380 | Dec 6, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -45,000 | $13.95 | $628k | 136,380 | Dec 6, 2024 |
| Dec 5, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +49,640 | $0.84 | $42k | 186,020 | Dec 6, 2024 |
| Dec 5, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -49,640 | $14.13 | $702k | 136,380 | Dec 6, 2024 |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +50,000 | $0.84 | $42k | 186,380 | Dec 6, 2024 |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -50,000 | $14.23 | $712k | 136,380 | Dec 6, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 149,640 | Dec 6, 2024 |
| Dec 5, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -49,640 | $0.00 | $0 | 100,000 | Dec 6, 2024 |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 50,000 | Dec 6, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +45,000 | $0.84 | $38k | 181,380 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -45,000 | $13.67 | $615k | 136,380 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +3,260 | $0.84 | $2,738 | 139,640 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +41,740 | $0.84 | $35k | 181,380 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -45,000 | $13.19 | $593k | 136,380 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 3,260 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -3,260 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -41,740 | $0.00 | $0 | 194,640 | Dec 4, 2024 |
| Nov 25, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -32,814 | $14.00 | $459k | 203,566 | Nov 27, 2024 |
| Nov 26, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -42,186 | $14.05 | $593k | 161,380 | Nov 27, 2024 |
| Nov 27, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -25,000 | $14.39 | $360k | 136,380 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.